8-KLeadership ChangesCorporate ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Nov 18, 2022)

Filed November 18, 2022For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on November 18, 2022, primarily detailing changes related to its executive team and corporate governance. The company announced the appointment of four new executive officers: Mark E. Delaney, Mark A. Gardner, Karthik Kuppusamy, and Patrick T. Plewman. These individuals have been elevated to executive officer roles and will participate in the company's Executive Officer Severance Plan, indicating a formalization of their roles and associated benefits. Additionally, Quest Diagnostics amended and restated its By-Laws, effective November 14, 2022. These revisions specifically address director nominations and proxy solicitations, including updates for compliance with Rule 14a-19 under the Securities Exchange Act of 1934. While these changes are largely procedural and clarifying, they signal the company's commitment to adhering to updated regulatory requirements and best practices in corporate governance.

Key Highlights

  • 1Four Senior Vice Presidents (Mark E. Delaney, Mark A. Gardner, Karthik Kuppusamy, Patrick T. Plewman) appointed as executive officers.
  • 2Newly appointed executive officers are now participants in the company's Executive Officer Severance Plan.
  • 3The company's By-Laws were amended and restated on November 14, 2022.
  • 4Amendments to By-Laws focus on director nominations and proxy solicitations.
  • 5The By-Law changes ensure compliance with Rule 14a-19 of the Securities Exchange Act of 1934.
  • 6These changes reflect an update to corporate governance procedures and regulatory alignment.

Frequently Asked Questions

This filing announces the appointment of four Senior Vice Presidents as executive officers and their inclusion in the Executive Officer Severance Plan. It also details amendments made to the company's By-Laws concerning director nominations and proxy solicitations, including compliance with SEC Rule 14a-19.

The new executive officers are Mark E. Delaney (Senior Vice President and Chief Commercial Officer), Mark A. Gardner (Senior Vice President, Molecular Genomics and Oncology), Karthik Kuppusamy (Senior Vice President, Clinical Solutions), and Patrick T. Plewman (Senior Vice President for Diagnostic Services).

The amendments to the By-Laws are primarily to update and clarify procedures related to director nominations and proxy solicitations, ensuring compliance with current SEC regulations, specifically Rule 14a-19. This suggests a proactive approach to corporate governance and shareholder communication.

This specific 8-K filing does not directly report on financial performance or outline major strategic shifts. The primary focus is on executive appointments and updates to corporate governance documents (By-Laws).